Kintor Pharmaceutical Collaborates with Fosun Pharma Development to Commercialise Proxalutamide for Treatment of COVID-19 in India and Africa

 

SUZHOU, China, July 14, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) today announced that it has entered into a licensing agreement with Shanghai Fosun Pharmaceutical Development Ltd. ("Fosun Pharma Development"), on the commercialisation of proxalutamide for the treatment of COVID-19 indication in India and 28 African countries  (the"Collaboration Regions"). Kintor and Fosun Pharma Development will collaborate on the emergency use authorization applications, promotion, and sales of proxalutamide for the treatment of COVID-19 indication. 

According to the licensing agreement, Fosun Pharma Development will be granted exclusive rights of registration and commercialisation of proxalutamide in the Collaboration Regions. Kintor Pharmaceutical will be eligible to receive upfront payment and milestone payments up to RMB560 million (upfront and development milestone payments up to RMB110 million and commercialisation milestone payments of RMB450 million). Kintor Pharmaceutical will also be eligible to receive royalty payments that are not less than 50% of the total operating profit in the Collaboration Regions, based on a tiered structure per the amount of net sales as agreed by both companies.

Proxalutamide is a new-generation androgen receptor (AR) antagonist. Since the outbreak of the COVID-19 pandemic in early 2020, Kintor Pharmaceutical has made rapid progress on the study on proxalutamide as a potential treatment for COVID-19 indication. 

In 2021, Kintor Pharmaceutical received approval from the U.S. Food and Drug Administration (FDA) and the Brazilian Health Regulatory Agency (ANVISA) to conduct phase III clinical trials with proxalutamide in patients with COVID-19. The company is now conducting two registered phase III multi-regional clinical trials (MRCT) of proxalutamide for the treatment of COVID-19 outpatients, and one phase III MRCT for COVID-19 inpatients in countries and regions including the United States, South America (including Brazil), the European Union, and Asia.   

Dr. Tong Youzhi, the founder, Chairman, and CEO of Kintor Pharmaceutical, commented, "The global COVID-19 pandemic continues to infect patients and devastate communities. Kintor hopes to accelerate emergency use authorizations for proxalutamide in developing countries severely affected by the pandemic to improve the lives of patients infected with COVID-19. With Fosun Pharma Group's excellent abilities in registration and commercialisation overseas, we hope to achieve win-win in the Collaboration Regions, so that more COVID-19 patients can be benefited from proxalutamide. "

About Proxalutamide

Proxalutamide is a nonsteroidal antiandrogen — specifically, a selective high-affinity silent antagonist of the androgen receptor — that is under development for the potential treatment of COVID-19, prostate cancer, and breast cancer. Proxalutamide is currently being studied in two registered phase III multi-regional clinical trials (MRCT) for the treatment of COVID-19 outpatients, and one phase III MRCT for inpatients with COVID-19 infection in the United States, South America (including Brazil), the European Union, and Asia.       

About Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited is developing and commercialising a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancer, alopecia, and acne. For more information, visit www.kintor.com.cn.

About Fosun Pharma Development

Shanghai Fosun Pharmaceutical Development Ltd. is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma Group";stock code: 600196.SH, 02196.HK) is a leading global pharmaceutical and healthcare provider in China. Fosun Pharma Group strategically operates businesses in the pharmaceutical and health industry, including pharmaceutical manufacturing, medical devices and medical diagnosis, healthcare services, and pharmaceutical distribution and retail. Fosun Pharma Group takes pharmaceutical manufacturing as its core business and sticks to innovative research and development. Through in-house R&D, co-development, in-licensing, and incubation, Fosun Pharma Group had established platforms for small molecule innovative drugs, antibody drugs, and cell therapy. For more information, please visit www.fosunpharma.com.

 

Cision View original content:https://www.prnewswire.com/news-releases/kintor-pharmaceutical-collaborates-with-fosun-pharma-development-to-commercialise-proxalutamide-for-treatment-of-covid-19-in-india-and-africa-301334264.html

SOURCE Kintor Pharmaceuticals

 
 
Company Codes: HongKong:9939
 

Back to news